<DOC>
	<DOCNO>NCT01460602</DOCNO>
	<brief_summary>This phase 1/2 Study VELCADE ( bortezomib ) , Nipent ( pentostatin ) , Rituxan ( rituximab ) ( VNR ) Subjects Relapsed Follicular , Marginal Zone , Mantle Cell Lymphoma .</brief_summary>
	<brief_title>Velcade , Nipent , Rituxan ( VNR ) Subjects With Relapsed Follicular , Marginal Zone , Mantle Cell Lymphoma</brief_title>
	<detailed_description>Number Subjects : During Phase 1 part study many 15 subject may enrol , base dose escalation scheme ; actual number subject enrol depend dose level maximum tolerate dose ( MTD ) establish . During Phase 2 part study , approximately 15 subject enrol order obtain total 30 response-evaluable subject . Study Objectives : The primary objective study : â€¢ Assess CR ORR follow treatment VELCADE ( bortezomib ) , Nipent ( pentostatin ) Rituxan ( rituximab ) ( VNR ) subject follicular lymphoma ( FL ) , marginal zone lymphoma ( MZL ) , mantle cell lymphoma ( MCL ) relapse refractory receive least 1 prior therapy . The secondary objective study : - Determine MTD VELCADE Nipent combination Rituxan ( VNR ) subject follicular lymphoma ( FL ) , marginal zone lymphoma ( MZL ) , mantle cell lymphoma ( MCL ) relapse refractory receive least 1 prior therapy - Evaluate safety tolerability VNR - Determine time response - Determine duration response - Determine time progression ( TTP ) - Determine progression free survival ( PFS ) rate - Determine 1-year survival - Determine overall survival ( OS )</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<criteria>1 . Voluntary write informed consent . 2 . Male female subject 18 year age old 3 . Karnofsky Performance Status ( KPS ) score 50 % . ECOG Performance Status score great 2 . 4 . Histologically confirm follicular Grade 13a , marginal zone mantle cell NHL . 5 . Relapsed progressive disease least 1 prior chemotherapy require treatment . 6 . Bidimensionally measurable disease least 1 lesion 2 cm single dimension 7 . Hematologic , hepatic , renal function parameter . 8 . Recovered fully significant toxicity associate prior surgery , radiation treatment , chemotherapy , biological therapy , autologous bone marrow stem cell transplant , investigational drug 9 . Expected survival 3 month 10 . Accepted birth control method treatment 12 month completion treatment . 1 . Follicular lymphoma Grade 3b 2 . History allergy study medication , analogue , murine protein , excipients various formulation 3 . Grade 2 peripheral neuropathy clinical examination within 14 day enrollment 4 . Serum creatinine 2.5 mg/dL within 14 day enrollment . 5 . Absolute neutrophil count ( ANC ) &lt; 1,000/L , platelet count &lt; 70,000/L within 14 day enrollment 6 . Aspartate transaminase ( AST [ SGOT ] ) alanine transaminase ( ALT/SGPT ] ) &gt; 2 x upper limit normal ( ULN ) , total bilirubin &gt; 3 ULN 7 . Rituxan refractory refractory antiCD20 radioimmunotherapy ( response prior Rituxan prior Rituxancontaining regimen , response TTP le 6 month ) 8 . Cancer radiotherapy , biological therapy , chemotherapy within 3 week prior Study Day 1 ( 6 week nitrosurea mytomycinC ) 9 . Prior lymphoma vaccine therapy within 12 month Study Day 1 10 . Prior antibody therapy lymphoma ( include radioimmunotherapy ) within 6 month prior Study Day 1 11 . Autologous bone marrow stem cell transplant within 6 month prior Study Day 1 12 . Known history hepatitis hepatic disease . 13 . Presence central nervous system ( CNS ) lymphoma 14 . Known history HIV infection AIDS 15 . Histologic transformation ( Follicular Marginal zone diffuse large B cell lymphoma [ DLBCL ] 16 . Presence pleural peritoneal effusion positive cytology lymphoma 17 . Another primary malignancy require active treatment 18 . Serious nonmalignant disease ( e.g. , congestive heart failure [ CHF ] , hydronephrosis ) ; active uncontrolled bacterial , viral , fungal infection ; condition ( include psychiatric ) , would compromise protocol objective n opinion Investigator and/or Sponsor 19 . New York Heart Association Class III IV ( Appendix D ) cardiac disease 20 . Major surgery , diagnostic surgery , within 4 week prior Study Day 1 21 . Female subject pregnant currently breastfeed 22 . Received investigational drug 14 day enrollment 23 . Hypersensitivity bortezomib , pentostatin , rituximab , boron mannitol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Follicular</keyword>
	<keyword>Marginal Zone</keyword>
	<keyword>Mantle Cell</keyword>
	<keyword>Velcade</keyword>
	<keyword>bortezomib</keyword>
	<keyword>Nipent</keyword>
	<keyword>pentastatin</keyword>
	<keyword>Rituxan</keyword>
	<keyword>rituximab</keyword>
	<keyword>Turturro</keyword>
	<keyword>Shreveport</keyword>
</DOC>